Combination of chemotherapy and mild hyperthermia using targeted nanoparticles: A potential treatment modality for breast cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F70883521%3A28610%2F23%3A63568199" target="_blank" >RIV/70883521:28610/23:63568199 - isvavai.cz</a>
Result on the web
<a href="https://www.mdpi.com/1999-4923/15/5/1389" target="_blank" >https://www.mdpi.com/1999-4923/15/5/1389</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/pharmaceutics15051389" target="_blank" >10.3390/pharmaceutics15051389</a>
Alternative languages
Result language
angličtina
Original language name
Combination of chemotherapy and mild hyperthermia using targeted nanoparticles: A potential treatment modality for breast cancer
Original language description
Despite the clinical benefits that chemotherapeutics has had on the treatment of breast cancer, drug resistance remains one of the main obstacles to curative cancer therapy. Nanomedicines allow therapeutics to be more targeted and effective, resulting in enhanced treatment success, reduced side effects, and the possibility of minimising drug resistance by the co-delivery of therapeutic agents. Porous silicon nanoparticles (pSiNPs) have been established as efficient vectors for drug delivery. Their high surface area makes them an ideal carrier for the administration of multiple therapeutics, providing the means to apply multiple attacks to the tumour. Moreover, immobilising targeting ligands on the pSiNP surface helps direct them selectively to cancer cells, thereby reducing harm to normal tissues. Here, we engineered breast cancer-targeted pSiNPs co-loaded with an anticancer drug and gold nanoclusters (AuNCs). AuNCs have the capacity to induce hyperthermia when exposed to a radiofrequency field. Using monolayer and 3D cell cultures, we demonstrate that the cell-killing efficacy of combined hyperthermia and chemotherapy via targeted pSiNPs is 1.5-fold higher than applying monotherapy and 3.5-fold higher compared to using a nontargeted system with combined therapeutics. The results not only demonstrate targeted pSiNPs as a successful nanocarrier for combination therapy but also confirm it as a versatile platform with the potential to be used for personalised medicine.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
21001 - Nano-materials (production and properties)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmaceutics
ISSN
1999-4923
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
5
Country of publishing house
CH - SWITZERLAND
Number of pages
23
Pages from-to
—
UT code for WoS article
000996877300001
EID of the result in the Scopus database
2-s2.0-85160659645